TP53 and cancer: RG7112 and AMG 232 are examples of small-molecule MDM2 inhibitors [22], which block the interaction between MDM2 and p53 and inhibit MDM2 from acting as a ubiquitin ligase, becoming the subject of preclinical and clinical research on their potential use in cancer therapy [22].